Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients

NCT00798070 is registered in ClinicalTrials.gov with Karolinska University Hospital as lead sponsor.

NCT NCT00798070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00798070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients
Lead sponsor
Karolinska University Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 28, 2007
Completion date
January 31, 2028
Enrollment
2,017 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer